Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization
Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization
Sonnet BioTherapeutics表示SON-1010的第一階段試驗顯示部分腫瘤反應，疾病穩定。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間